Emma Dean

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada et al. · Nature Communications · 2019 · 327 citations · Full text

AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations

David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue et al. · Journal of Clinical Oncology · 2017 · 315 citations · Full text

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

Dominic G. Rothwell, Mahmood Ayub, Natalie Cook et al. · Nature Medicine · 2019 · 302 citations

Genetic Testing, Oncology, Cancer Detection +11

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau et al. · EClinicalMedicine · 2021 · 250 citations · Full text

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Johann S. de Bono, Nicole Concin, David S. Hong et al. · The Lancet Oncology · 2019 · 217 citations · Full text

Innovatv 201, Tisotumab Vedotin, Medicine +10